Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?

被引:3
|
作者
Macapagal, Sharina C. [1 ,4 ]
Bennani, N. Nora [2 ,3 ]
机构
[1] Mayo Clin, Dept Mol Med, Rochester, MN USA
[2] Mayo Clin, Dept Med, Div Hematol, Rochester, MN USA
[3] Mayo Clin, Coll Med, 200 First St SW, Rochester, MN 55905 USA
[4] Mayo Clin, 200 First St SW, Rochester, MN 55905 USA
关键词
Peripheral T-cell lymphoma; Epigenetic modifiers; Antibody-drug conjugates; Small molecule inhibitors; Oncolytic virotherapy; PROGRAMMED DEATH-1 PD-1; PHASE-I; BRENTUXIMAB VEDOTIN; INHIBITOR; MUTATIONS; ROMIDEPSIN; TRIAL; TET2; REARRANGEMENTS; IMMUNOTHERAPY;
D O I
10.1016/j.blre.2023.101071
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Peripheral T-cell lymphomas (PTCLs) are a diverse and uncommon type of lymphoid malignancies with a dismal prognosis. Recent advances in genomic studies have shown recurring mutations that are changing our knowledge of the disease's molecular genetics and pathogenesis. As such, new targeted therapies and treatments to improve disease outcomes are currently being explored. In this review, we discussed the current understanding of the nodal PTCL biology with potential therapeutic implications and gave our insights on the promising novel therapies that are currently under study such as immunotherapy, chimeric antigen receptor T-cell therapy, and oncolytic virotherapy.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Chemotherapy-Free Treatment of Follicular Lymphoma: We Have the Ingredients, Now for Some Recipes
    Cheah, Chan Yoon
    Fowler, Nathan H.
    ONCOLOGY-NEW YORK, 2015, 29 (10): : 769 - 772
  • [42] NODAL PERIPHERAL T-CELL LYMPHOMA (PTCL): CHARACTERISTICS, PROGNOSIS AND OUTCOME OF 120 PATIENTS
    Angelopoulou, M.
    Tsirigotis, P.
    Galani, Z.
    Moschogiannis, M.
    Dimou, M.
    Tsirkinidis, P.
    Masouridi, S.
    Gainarou, G.
    Dimitriadou, E.
    Sachanas, S.
    Yiakoumis, X.
    Pappa, V.
    Papageorgiou, L.
    Boutsikas, G.
    Kalpadakis, C.
    Flevari, P.
    Koutsi, K.
    Sinni, E.
    Kyrtsonis, M. C.
    Panayiotidis, P.
    Siakantaris, M.
    Dervenoulas, I.
    Meletis, I.
    Pangalis, G.
    Vassilakopoulos, T.
    HAEMATOLOGICA, 2012, 97 : 656 - 657
  • [43] PERIPHERAL T-CELL LYMPHOMA PTCL
    Hamed, Hanan
    LEUKEMIA RESEARCH, 2017, 61 : S10 - S11
  • [44] PERIPHERAL T-CELL LYMPHOMA OF THE SCROTUM
    DOLL, DC
    DIAZARIAS, A
    ACTA HAEMATOLOGICA, 1994, 91 (02) : 77 - 79
  • [45] Peripheral T-cell lymphoma of the eyelid
    Ishikawa, Makoto
    Watabe, Hiroshi
    Hayakawa, Masahiro
    Yoshitomi, Takeshi
    CLINICAL OPHTHALMOLOGY, 2009, 3 : 527 - 529
  • [47] PERIPHERAL T-CELL LYMPHOMA - AN OVERVIEW
    HALL, PA
    RICHARDS, MA
    LEUKEMIA & LYMPHOMA, 1990, 2 (06) : 381 - 384
  • [48] Romidepsin for peripheral T-cell lymphoma
    Khot, Amit
    Dickinson, Michael
    Prince, H. Miles
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (04) : 351 - 359
  • [49] Peripheral T-cell lymphoma.
    Au W.Y.
    Liang R.
    Current Oncology Reports, 2002, 4 (5) : 434 - 442
  • [50] Belinostat for Peripheral T-Cell Lymphoma
    Radeski, Dejan
    Sawas, Ahmed
    O'Connor, Owen A.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2014, 10 (04) : 12 - 14